Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855342 | 0.77 | GBA1 (0.46) | GBA1ATMALDH1A1MBOAT4NPC1 | |
| SCHEMBL533909 | 0.76 | IDO1 (0.41) | ALDH1A1NPC1GAARAB9A | |
| SCHEMBL2147686 | 0.76 | GBA1 (0.40) | GBA1ATMALDH1A1MBOAT4NPC1 | |
| SCHEMBL1816193 | 0.74 | GBA1 (0.47) | GBA1ATMALDH1A1MBOAT4NPC1 | |
| SCHEMBL12085800 | 0.72 | GBA1 (0.35) | GBA1ATMALDH1A1MBOAT4 | |
| SCHEMBL29548286 | 0.71 | GBA1 (0.44) | GBA1ATMALDH1A1MBOAT4NPC1 | |
| SCHEMBL6478582 | 0.69 | GBA1 (0.39) | GBA1ATMALDH1A1MBOAT4NPC1 | |
| SCHEMBL14659317 | 0.69 | RAB9A (0.40) | ATMALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14659458 | 0.68 | GBA1 (0.37) | GBA1ATMALDH1A1MBOAT4NPC1 | |
| SCHEMBL21911797 | 0.68 | GBA1 (0.41) | GBA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | GBA1 1789/4885SCN9A 3360/4885KCNH2 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.